Kent Holtorf

I am the medical director of Holtorf Medical Group, where we specialize in difficult to treat, multi-system illness, chronic infections, and immune-mediated conditions. I have found phages to be very effective for particular patients that were unresponsive to other cutting-edge therapies.

I am the founder and president of Integrative Peptides and other startup healthcare and biotech companies that commercialize innovative therapies and testing to bring them from the benchtop to doctors and their patients. I am always interested in collaborations and opportunities and feel that, much like peptides (and other innovative therapies), the potential of phages is enormous. They both have been hindered by a lack of knowledge, regulatory hurdles, and supply chain fragmentation that require out-of-the-box thinking, along with regulatory expertise to bring the products to market via unique regulatory and logistic pathways and drive sales through numerous pathways of physician and patient education.